Properties (61)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Astra_AB
gptkb:MedImmune |
| gptkbp:awards |
Innovation Award 2021
Top Employer Global 2021 Best Workplaces 2020 |
| gptkbp:CEO |
gptkb:Pascal_Soriot
|
| gptkbp:clinicalTrials |
patient registries
collaborative studies Phase III trials Phase I trials Phase II trials real-world evidence studies |
| gptkbp:collaborations |
government agencies
non-profit organizations academic institutions global health initiatives |
| gptkbp:communityEngagement |
health education programs
volunteer programs patient support initiatives |
| gptkbp:employees |
70,600 (2020)
|
| gptkbp:financialPerformance |
dividend payments
strong growth in emerging markets shareholder returns |
| gptkbp:founded |
1999
|
| gptkbp:globalPresence |
manufacturing facilities worldwide
operations in over 100 countries research centers globally |
| gptkbp:headquarters |
gptkb:Cambridge,_England
gptkb:Cambridge_Biomedical_Campus |
| https://www.w3.org/2000/01/rdf-schema#label |
AstraZeneca PLC
|
| gptkbp:impact |
gptkb:AstraZeneca/Oxford_vaccine
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:investmentFocus |
research and development
biotechnology |
| gptkbp:market |
$140 billion (2021)
new cancer therapies new cardiovascular drugs new respiratory treatments |
| gptkbp:marketSegment |
strategic partnerships
focus on innovation expansion_in_Asia |
| gptkbp:partnerships |
gptkb:University_of_Oxford
|
| gptkbp:patentCitation |
vaccines
biologics pharmaceutical compounds |
| gptkbp:products |
vaccines
|
| gptkbp:researchFocus |
oncology
immunology cardiovascular respiratory |
| gptkbp:revenue |
$37 billion (2020)
|
| gptkbp:stockSymbol |
AZN
|
| gptkbp:subsidiary |
gptkb:AstraZeneca_AB
gptkb:AstraZeneca_UK_Limited gptkb:Alexion_Pharmaceuticals gptkb:AstraZeneca_Canada_Inc. |
| gptkbp:sustainability |
environmental initiatives
social responsibility governance practices |
| gptkbp:website |
www.astrazeneca.com
|